|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.03/0.08
|
企業價值
1.39B
|
資產負債 |
每股賬面淨值
-1.35
|
現金流量 |
現金流量率
--
|
損益表 |
收益
901.00M
|
每股收益
8.07
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world. |